A biologic is a medicine made using a living system, and historically this was often an animal. Most products being developed as biosimilars are recombinant proteins, or proteins derived from genetically engineered DNA. In this report is a biologic defined as proteins, peptides, hormones or antibodies drugs production by bio-engineered technology, but does not include a vaccine.
Most of biologics manufacturer are concentrated in US, Germany,UK and other developed countries. But in biosimilars industry the situation is different, manufacturer in developing countries play a very important role.
Through the research we tend to believe that the growth of biologics industry maybe slow but high profits during the period of patent may attractive. As to biosimilars, now is a changce for newcomers and they will greatly change the industry.
According to this study, over the next five years the Biologics and Biosimilars market will register a 4.5% CAGR in terms of revenue, the global market size will reach US$ 272400 million by 2024, from US$ 209400 million in 2019. In particular, this report presents the global market share (sales and revenue) of key companies in Biologics and Biosimilars business, shared in Chapter 3.
This report presents a comprehensive overview, market shares, and growth opportunities of Biologics and Biosimilars market by product type, application, key manufacturers and key regions and countries.
This study considers the Biologics and Biosimilars value and volume generated from the sales of the following segments:
Segmentation by product type: breakdown data from 2014 to 2019, in Section 2.3: and forecast to 2024 in section 11.7.
Monoclonal Antibodies
Interferon
Erythropoietin
Insulin
Vaccines
Other
Segmentation by application: breakdown data from 2014 to 2019, in Section 2.4: and forecast to 2024 in section 11.8.
Tumor
Diabetes
Cardiovascular
Hemophilia
Other
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Spain
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in in Chapter 3.
Roche
Amgen
AbbVie
Sanofi-Aventis
Johnson & Johnson
Pfizer
Novo Nordisk
Eli Lilly
Novartis
Merck
3sbio
Changchun High Tech
CP Guojian
Biotech
Gelgen
Innovent
Dong Bao
Ganlee
In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.
Research objectives
To study and analyze the global Biologics and Biosimilars consumption (value & volume) by key regions/countries, product type and application, history data from 2014 to 2018, and forecast to 2024.
To understand the structure of Biologics and Biosimilars market by identifying its various subsegments.
Focuses on the key global Biologics and Biosimilars manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
To analyze the Biologics and Biosimilars with respect to individual growth trends, future prospects, and their contribution to the total market.
To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
To project the consumption of Biologics and Biosimilars submarkets, with respect to key regions (along with their respective key countries).
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
To strategically profile the key players and comprehensively analyze their growth strategies.
